Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus
Sponsor: Enanta Pharmaceuticals, Inc
Summary
Zelicapavir is a novel, orally administered, nonfusion replication inhibitor of RSV. It is being investigated in this Phase 2 study (EDP 938-203) as a potential treatment for RSV infection in both hospitalized and non-hospitalized children aged ≥28 days to ≤36 months who present with symptomatic RSV infection.
Official title: Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zelicapavir in Participants ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus
Key Details
Gender
All
Age Range
28 Days - 36 Months
Study Type
INTERVENTIONAL
Enrollment
150
Start Date
2026-07
Completion Date
2026-12
Last Updated
2026-03-19
Healthy Volunteers
No
Interventions
zelicapavir
Oral suspension
Placebo
Placebo oral suspension to match zelicapavir